• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Treatment of canine epilepsy with primidone.

作者信息

Schwartz-Porsche D, Löscher W, Frey H H

出版信息

J Am Vet Med Assoc. 1982 Sep 15;181(6):592-5.

PMID:7141952
Abstract

Forty-seven dogs with a history of generalized recurrent seizures were treated with primidone at a daily oral dosage of 13 to 100 mg/kg of body weight, divided into 2 to 3 doses. During treatment, plasma concentrations of primidone and its metabolites, phenobarbital and phenylethylmalonamide, were determined at irregular intervals. Of the 30 dogs that finally could be evaluated, 20 were brought to excellent or good control of their seizures by daily primidone dosages ranging from 13 to 17 mg/kg and at plasma phenobarbital concentrations of 6 to 37 micrograms/ml. Of the other 10 dogs, 5 improved to a minor extent and 5 did not improve at all. It was concluded that treatment of seizures should start with a daily dosage of 10 to 15 mg/kg, with the dosage being increased to about 35 mg/kg within a few weeks. For dogs in which the seizures are not controlled by this dosage, a further increase should be tried until a plasma phenobarbital concentration of 30 to 40 micrograms/ml is reached or until signs of drug toxicosis develop. Monitoring of plasma phenobarbital concentrations is sufficient for the control of treatment with primidone.

摘要

相似文献

1
Treatment of canine epilepsy with primidone.
J Am Vet Med Assoc. 1982 Sep 15;181(6):592-5.
2
Serum concentrations and efficacy of phenytoin, phenobarbital, and primidone in canine epilepsy.苯妥英钠、苯巴比妥和扑米酮在犬癫痫中的血清浓度及疗效
J Am Vet Med Assoc. 1984 May 1;184(9):1117-20.
3
Efficacy of primidone in dogs with seizures unresponsive to phenobarbital.
J Am Vet Med Assoc. 1984 Oct 15;185(8):867-8.
4
Therapeutic serum concentrations of primidone and its metabolites, phenobarbital and phenylethylmalonamide in epileptic dogs.癫痫犬体内扑米酮及其代谢产物苯巴比妥和苯乙丙二酰胺的治疗血清浓度。
J Am Vet Med Assoc. 1983 May 15;182(10):1091-4.
5
Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison.苯巴比妥和扑米酮对犬癫痫的治疗效果比较
J Vet Pharmacol Ther. 1985 Jun;8(2):113-9. doi: 10.1111/j.1365-2885.1985.tb00934.x.
6
Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996).单用溴化钾或与其他抗惊厥药联合治疗的癫痫犬的治疗性血清药物浓度:122例(1992 - 1996年)
J Am Vet Med Assoc. 1998 Nov 15;213(10):1449-53.
7
[Effectiveness of bromide in therapy resistant epilepsy of dogs].[溴化物在犬难治性癫痫治疗中的有效性]
Tierarztl Prax. 1991 Aug;19(4):395-401.
8
Serum concentrations of primidone and its metabolites, phenylethylmalonamide and phenobarbital, in the dog.犬体内扑米酮及其代谢产物苯乙基丙二酰胺和苯巴比妥的血清浓度。
Am J Vet Res. 1980 Oct;41(10):1643-5.
9
[Pharmacologic principles in the treatment of epilepsy in the dog and cat].[犬猫癫痫治疗中的药理学原理]
Tierarztl Prax. 1985;13(4):541-9.
10
Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures.低亲和力部分苯二氮䓬受体激动剂ELB 138在犬癫痫模型及自发性反复癫痫发作犬中的抗惊厥疗效。
Epilepsia. 2004 Oct;45(10):1228-39. doi: 10.1111/j.0013-9580.2004.21204.x.

引用本文的文献

1
Antiepileptic drugs' tolerability and safety--a systematic review and meta-analysis of adverse effects in dogs.抗癫痫药物的耐受性和安全性——犬类不良反应的系统评价和荟萃分析
BMC Vet Res. 2016 May 21;12:79. doi: 10.1186/s12917-016-0703-y.
2
2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs.2015年美国兽医内科学会犬癫痫发作管理小动物共识声明。
J Vet Intern Med. 2016 Mar-Apr;30(2):477-90. doi: 10.1111/jvim.13841. Epub 2016 Feb 22.
3
Treatment in canine epilepsy--a systematic review.犬癫痫的治疗——一项系统评价。
BMC Vet Res. 2014 Oct 22;10:257. doi: 10.1186/s12917-014-0257-9.